Immune Fingerprints in Blood Reveal Parkinson’s Disease When Patients Are Sorted First

For decades, one of the most tantalizing ideas in neurodegenerative disease research has been that a simple blood test could detect Parkinson’s disease long before tremors and rigidity appear. The immune system, in principle, should leave traces of the disease in circulation: T cells that have encountered misfolded proteins in the brain ought to carry recognizable molecular signatures. Yet every serious attempt to build a diagnostic from the T-cell receptor (TCR) repertoire has run into the same wall. Patients with idiopathic Parkinson’s disease (iPD) did not appear to share convergent TCR sequence motifs, the kind of common patterns that have made repertoire-based diagnostics feasible in infectious disease and cancer immunology. A new study published in Genome Medicine argues that this wall was never real. It was an artifact of treating a biologically heterogeneous patient population as if it were a single group.

The research, led by Jiayu Chen, Xian Xia, and Gang Hu of Nanjing Medical University together with colleagues at Nanjing University of Chinese Medicine and Shanghai Jiao Tong University School of Medicine, takes a deliberately contrarian approach. Rather than pooling all Parkinson’s patients into one diagnostic model, the team first stratified them into molecularly informed subtypes, and only then trained subtype-specific classifiers. The result is striking: within each subtype, multimodal classifiers built on TCR repertoire data achieved an area under the curve (AUC) exceeding 0.8, a level of performance that many considered unattainable for a peripheral blood immune signature in a neurodegenerative disease.

The central insight of the study is that the apparent absence of shared TCR features among Parkinson’s patients likely reflects two intertwined problems: insufficient sample sizes and unaccounted immune heterogeneity within the patient population. T-cell repertoires are enormously diverse. Each person’s body carries millions of distinct TCR clonotypes, generated by stochastic recombination of gene segments and shaped by a lifetime of viral infections, environmental exposures, and immune challenges. Cytomegalovirus alone, which infects a large fraction of adults, imprints durable and highly individual patterns onto the repertoire. When disease-driven TCR signals are weak relative to this background noise, and when patients are grouped together despite having immunologically distinct forms of the disease, any convergent motif shared by a subset of patients is diluted into invisibility.

To solve the stratification problem, the researchers turned to an unusual source of structure: laboratory mice. They reconstructed TCR repertoires from the two largest idiopathic Parkinson’s disease cohorts currently available, drawing on data from the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Disease Biomarkers Program (PDBP), both accessible through the Accelerating Medicines Partnership Parkinson’s Disease knowledge platform. These human datasets were then anchored against three mechanistically distinct mouse models of Parkinson’s disease, including models involving the mitochondrial toxin MPTP and alpha-synuclein pre-formed fibrils, which reproduce different facets of the human pathology. By asking which human patients most resembled which model at the molecular level, the team could sort patients into model-anchored informed subtypes without needing to know in advance what those subtypes were.

This cross-species anchoring strategy is the methodological heart of the paper. Mouse models are often criticized for their imperfect fidelity to human disease, but the authors exploited them in a way that sidesteps that criticism. The models were not used as stand-ins for human Parkinson’s disease; they were used as molecular reference points, each representing a defined mechanism of neurodegeneration. A patient whose blood transcriptome and immune profile aligned with, say, an alpha-synuclein-driven model was assigned to a different subtype than a patient whose profile resembled a toxin-based model. The approach, which the authors describe with tools such as mouse-anchored pathway analysis for disease trajectories, converts a fuzzy clinical category into a set of mechanistically interpretable groups.

Once patients were stratified, the diagnostic modeling became tractable. Within each subtype, the team trained multimodal multiple-instance learning classifiers, a machine learning framework well suited to repertoire data because it can aggregate information across thousands of individual TCR clonotypes without requiring any single clonotype to be present in every patient. This matters because TCR responses to a given antigen are typically public only in part: some sequence motifs recur across individuals, but many are private. Multiple-instance learning lets the classifier learn the collective statistical signature of a disease-reactive repertoire rather than hunting for one magic sequence. Combined with multimodal inputs, the classifiers captured patterns that single-feature approaches would have missed.

The reported performance, with AUC values above 0.8 for both subtypes, is notable in a field where peripheral biomarkers for Parkinson’s disease have struggled to reach clinical utility. Current diagnostic practice relies on motor symptoms, which appear only after substantial loss of dopaminergic neurons in the substantia nigra, and on imaging and cerebrospinal fluid markers that are invasive or expensive. Alpha-synuclein seed amplification assays have recently advanced the field, but a blood-based immune readout would offer a complementary, minimally invasive window into disease biology, potentially usable for screening, monitoring, and patient stratification in clinical trials.

Equally important is the study’s broader lesson about immune-based diagnostics in complex diseases. The authors frame their findings as evidence that disease stratification is a prerequisite, not an afterthought, for TCR repertoire modeling in neurodegeneration. The same logic may explain past failures in other conditions. Immune signatures of chronic obstructive pulmonary disease, cancer, and viral infection have all been shown to depend on how patients are grouped, and the team explicitly drew on previously published COPD and cytomegalovirus TCR datasets to contextualize their Parkinson’s findings. If a disease population contains two or three immunologically distinct subgroups, a single pooled model will fail even when each subgroup carries a perfectly detectable signature. The diagnostic signal does not disappear; it is simply averaged away.

The work also carries implications beyond diagnosis. If model-anchored subtypes correspond to distinct mechanisms of neurodegeneration, they could guide the selection of patients for mechanism-targeted therapies, a persistent challenge in Parkinson’s drug development where candidate drugs may benefit only the subset of patients whose disease follows the matched pathway. The stratification framework, built entirely from peripheral blood data, could in principle be applied at scale to existing cohort studies and biobanks. The authors emphasize that their analysis involved secondary use of de-identified datasets from PPMI, PDBP, and prior studies, with animal work approved by the Institutional Animal Care and Use Committee of Nanjing Medical University.

Caveats remain, as they do for any machine learning study of human immune data. The classifiers were developed within the largest available cohorts, and independent prospective validation will be essential before any clinical deployment. Repertoire data are sensitive to technical factors such as sample handling and sequencing depth, and the authors accounted for quality metrics including RNA integrity in their pipeline. Still, the conceptual advance is clear and likely durable: the immune system does carry readable traces of Parkinson’s disease, but only when researchers first acknowledge that Parkinson’s disease is not one immunological entity. By combining cross-species molecular stratification with modern machine learning, the study transforms a long-standing negative result, the absence of convergent TCR motifs in Parkinson’s patients, into a roadmap for finding them, and offers a template that other fields chasing elusive blood-based biomarkers may soon follow.

Subject of Research: T-cell receptor repertoire-based diagnosis and immune stratification of idiopathic Parkinson's disease

Article Title: Cross-species molecular stratification enables T cell receptor diagnosis of Parkinson’s disease

Article References: Chen, J., Xia, X., Zhang, Y., Tong, X., Liang, Y., Fan, X., Meng, Q., Wei, Y., & Hu, G. (2026). Cross-species molecular stratification enables T cell receptor diagnosis of Parkinson’s disease. Genome Medicine. https://doi.org/10.1186/s13073-026-01776-x

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01776-x

Keywords: Parkinson's disease, T-cell receptor, TCR repertoire, immune stratification, machine learning, biomarkers, neuroimmunology, cross-species analysis, mouse models, alpha-synuclein, blood test, Genome Medicine